ETOMSEarly Treatment of Multiple Sclerosis (treatment study)
ETOMSEngineering, Technical Operations and Maintenance Services (Qantas Airways; Australia)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
In an analysis of MRI data from the ETOMS study, the reduction in brain volume at 24 months after the start of treatment was significantly lower for patients who received IFNB-1a than for those who received placebo (p = .0031; Filippi et al., 2004).
Rebif was tested in the ETOMS trial (2001); [30] 308 subjects were randomised to receive either 22 [micro]g Rebif or placebo SC weekly.
While CHAMPS and ETOMS data are under consideration by the FDA, which is expected to approve it in the U.S., a multi-center trial of Betaseron for people who might have MS has just begun in Europe, Canada, and Israel.
CIS or First Demyelinating Event Placebo-Controlled Studies Trial Agent Tested (a) Dose PreCISe GA (Copaxone) 20 mg/day sc BENEFIT High-dose IFN[beta]-lb (Betaseron) 250 [micro]g qod sc CHAMPS Low-dose IFN[beta]-1a (Avonex) 30 [micro]g/week im ETOMS Low-dose IFN[beta]-1a (Rebif) 22 [micro]g/week sc REFLEX High-dose IFN[beta]-1a (Rebif) 44 [micro]g tiw or once a week Risk Reduction for Conversion Trial to CDMS at 2 Years (%) PreCISe 45 BENEFIT 50 CHAMPS 44 (b) ETOMS 39 REFLEX Ongoing Note.
The Early Treatment Of MS (ETOMS) study reported similar findings after 2 years of weekly subcutaneous (sc) injections of IFNB-1a (22 [micro]g; Rebif[R]; n = 154) compared with placebo (n = 155) in patients with a first episode of neurological dysfunction suggestive of MS (100).